LUNG
Companies
NASDAQ
Pulmonx Corporation
Health Care
$2.58
-$4.21 (-62.00%)
Price Chart
Overview
About LUNG
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Market Cap
$269.4M
Volume
864.1K
Avg. Volume
1.1M
P/E Ratio
-2.09375
Dividend Yield
0.00%
Employees
257.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.23
Moderate Correlation
Volatility
High (0.74)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, LUNG shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$269.4M
Volume864.1K
P/E Ratio-2.09
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
July 29, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025